NASDAQ:ACAD - ACADIA Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $32.76
  • Forecasted Upside: 56.99 %
  • Number of Analysts: 19
  • Breakdown:
  • 0 Sell Ratings
  • 12 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$20.87
▼ -0.6 (-2.79%)
1 month | 3 months | 12 months
Get New ACADIA Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACAD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACAD

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$32.76
▲ +56.99% Upside Potential
This price target is based on 19 analysts offering 12 month price targets for ACADIA Pharmaceuticals in the last 3 months. The average price target is $32.76, with a high forecast of $57.00 and a low forecast of $18.00. The average price target represents a 56.99% upside from the last price of $20.87.
Hold
The current consensus among 19 investment analysts is to hold stock in ACADIA Pharmaceuticals. This rating has held steady since February 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 7 buy ratings
  • 7 hold ratings
  • 0 sell ratings
10/30/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 7 hold ratings
  • 0 sell ratings
1/28/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 10 hold ratings
  • 0 sell ratings
4/27/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 9 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 9 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 9 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 12 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 12 hold ratings
  • 0 sell ratings
4/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 12 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2021The Goldman Sachs GroupReiterated RatingBuy ➝ Neutral$73.00 ➝ $25.00Low
i
4/13/2021Jefferies Financial GroupReiterated RatingBuy ➝ Hold$40.00 ➝ $21.00Low
i
4/13/2021MizuhoReiterated RatingBuy ➝ Neutral$25.00Low
i
4/13/2021Canaccord GenuityReiterated RatingBuy ➝ Hold$40.00 ➝ $26.00Low
i
4/13/2021Morgan StanleyLower Price TargetOverweight$50.00 ➝ $28.00Low
i
4/13/2021HC WainwrightReiterated RatingBuy ➝ Neutral$43.00 ➝ $18.00N/A
i
Rating by A. Fein at HC Wainwright
4/7/2021HC WainwrightDowngradeBuy ➝ Neutral$43.00 ➝ $18.00Medium
i
Rating by A. Fein at HC Wainwright
4/6/2021SVB LeerinkLower Price TargetOutperform$63.00 ➝ $31.00Low
i
4/6/2021Morgan StanleyLower Price TargetOverweight$50.00 ➝ $28.00Low
i
4/6/2021Cantor FitzgeraldBoost Price TargetOverweight$33.00 ➝ $45.00Low
i
4/6/2021Canaccord GenuityDowngradeBuy ➝ Hold$40.00 ➝ $26.00Low
i
4/6/2021MizuhoDowngradeBuy ➝ Neutral$37.00 ➝ $25.00Low
i
4/6/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$40.00 ➝ $21.00Low
i
4/5/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$73.00 ➝ $25.00High
i
4/5/2021Raymond JamesDowngradeOutperform ➝ Market PerformHigh
i
4/5/2021Needham & Company LLCLower Price TargetBuy$44.00 ➝ $30.00High
i
3/16/2021Bank of AmericaReiterated RatingBuy ➝ NeutralHigh
i
3/15/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellReiterated RatingBuy ➝ Neutral$66.00 ➝ $35.00Low
i
3/15/2021HC WainwrightLower Price TargetBuy$60.00 ➝ $43.00N/A
i
3/15/2021Needham & Company LLCLower Price TargetBuy$60.00 ➝ $44.00N/A
i
3/15/2021Stifel NicolausReiterated RatingBuy ➝ Hold$68.00 ➝ $27.00N/A
i
3/15/2021Raymond JamesReiterated RatingStrong-Buy ➝ Outperform$65.00 ➝ $35.00N/A
i
3/15/2021Morgan StanleyLower Price TargetOverweight$65.00 ➝ $50.00N/A
i
3/15/2021Canaccord GenuityLower Price TargetBuy$61.00 ➝ $40.00N/A
i
3/15/2021GuggenheimReiterated RatingBuy ➝ NeutralN/A
i
3/15/2021CitigroupReiterated RatingBuy ➝ Neutral$66.00 ➝ $35.00N/A
i
3/10/2021Bank of AmericaDowngradeBuy ➝ NeutralHigh
i
3/9/2021GuggenheimDowngradeBuy ➝ NeutralHigh
i
3/9/2021Morgan StanleyLower Price TargetOverweight$65.00 ➝ $50.00High
i
3/9/2021CowenLower Price TargetOutperform$66.00 ➝ $57.00High
i
3/9/2021OppenheimerLower Price TargetMarket Perform$42.00 ➝ $28.00High
i
3/9/2021Canaccord GenuityLower Price TargetBuy$61.00 ➝ $40.00High
i
3/9/2021CitigroupDowngradeBuy ➝ Neutral$66.00 ➝ $35.00High
i
3/9/2021Needham & Company LLCLower Price TargetBuy$60.00 ➝ $44.00High
i
3/9/2021MizuhoLower Price TargetBuy$70.00 ➝ $55.00High
i
3/9/2021HC WainwrightLower Price TargetBuy$60.00 ➝ $43.00High
i
3/9/2021Royal Bank of CanadaLower Price TargetOutperform$60.00 ➝ $36.00High
i
3/9/2021Stifel NicolausDowngradeBuy ➝ Hold$68.00 ➝ $27.00High
i
3/9/2021Raymond JamesDowngradeStrong-Buy ➝ Outperform$65.00 ➝ $35.00High
i
3/3/2021Morgan StanleyBoost Price TargetOverweight$60.00 ➝ $65.00Low
i
3/2/2021Royal Bank of CanadaBoost Price TargetOutperform$55.00 ➝ $63.00High
i
2/25/2021Morgan StanleyBoost Price TargetOverweight$60.00 ➝ $65.00High
i
2/24/2021MizuhoReiterated RatingBuy$69.00 ➝ $70.00Medium
i
12/29/2020Cantor FitzgeraldReiterated RatingOverweight$61.00 ➝ $70.00N/A
i
12/16/2020Morgan StanleyBoost Price TargetOverweight$58.00 ➝ $60.00Low
i
12/15/2020MizuhoInitiated CoverageBuy$69.00Medium
i
11/16/2020Raymond JamesUpgradeOutperform ➝ Strong-Buy$65.00High
i
11/5/2020Morgan StanleyBoost Price TargetOverweight$57.00 ➝ $58.00Medium
i
10/13/2020Morgan StanleyBoost Price TargetOverweight$55.00 ➝ $57.00Low
i
8/24/2020Raymond JamesInitiated CoverageOutperform$65.00Low
i
8/20/2020Morgan StanleyInitiated CoverageOverweight$55.00Medium
i
8/6/2020HC WainwrightReiterated RatingBuyHigh
i
Rating by A. Fein at HC Wainwright
8/6/2020Needham & Company LLCReiterated RatingBuy$60.00Low
i
Rating by Alan Carr at Needham & Company LLC
8/6/2020Canaccord GenuityBoost Price TargetBuy$56.00 ➝ $60.00Low
i
8/6/2020SVB LeerinkLower Price TargetOutperform$56.00 ➝ $52.00Medium
i
8/6/2020OppenheimerReiterated RatingHold$42.00Medium
i
7/28/2020Canaccord GenuityReiterated RatingHold$29.00Low
i
7/21/2020Jefferies Financial GroupReiterated RatingBuy$60.00High
i
Rating by Chris Howerton at Jefferies Financial Group Inc.
7/21/2020CitigroupLower Price Target$69.00 ➝ $63.00High
i
Rating by Neena Bitritto-Garg at Citigroup Inc.
7/21/2020Cantor FitzgeraldLower Price TargetOverweight$63.00 ➝ $61.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
7/21/2020OppenheimerLower Price TargetPositive ➝ Market Perform$53.00 ➝ $42.00High
i
7/21/2020Royal Bank of CanadaLower Price TargetOutperform$61.00 ➝ $55.00High
i
7/16/2020Needham & Company LLCInitiated CoverageBuy$60.00Low
i
Rating by Alan Carr at Needham & Company LLC
7/9/2020Royal Bank of CanadaBoost Price TargetPositive ➝ Outperform$58.00 ➝ $61.00Low
i
7/6/2020Stifel NicolausUpgradeHold ➝ Buy$41.00 ➝ $71.00High
i
5/27/2020OppenheimerBoost Price TargetMarket Perform$48.00 ➝ $53.00Medium
i
5/8/2020JPMorgan Chase & Co.Boost Price TargetOverweight$50.00 ➝ $55.00Medium
i
5/8/2020OppenheimerReiterated RatingHold$48.00High
i
5/8/2020Cantor FitzgeraldBoost Price TargetBuy$58.00 ➝ $63.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
5/8/2020Needham & Company LLCReiterated RatingBuyHigh
i
4/16/2020Jefferies Financial GroupInitiated CoverageBuy$60.00Low
i
3/31/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$45.00 ➝ $72.00High
i
3/5/2020CitigroupInitiated CoverageBuy$69.00High
i
3/5/2020CowenReiterated RatingBuy$66.00Medium
i
Rating by Ritu Baral at Cowen Inc
2/27/2020HC WainwrightReiterated RatingBuy$60.00High
i
Rating by Andrew Fein at HC Wainwright
2/27/2020Cantor FitzgeraldReiterated RatingOverweight$70.00 ➝ $75.00High
i
2/26/2020JPMorgan Chase & Co.Set Price TargetOutperform$50.00Medium
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
1/19/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
1/14/2020CowenReiterated RatingBuy$66.00High
i
Rating by Ritu Baral at Cowen Inc
12/16/2019GuggenheimInitiated CoverageBuy$60.00High
i
12/5/2019HC WainwrightReiterated RatingBuy$60.00High
i
Rating by Andrew Fein at HC Wainwright
12/5/2019CowenReiterated RatingBuy$66.00High
i
Rating by Ritu Baral at Cowen Inc
11/27/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
11/26/2019Cantor FitzgeraldBoost Price TargetOverweight$63.00 ➝ $70.00Low
i
11/26/2019CowenInitiated CoverageBuy$66.00Low
i
Rating by Ritu Baral at Cowen Inc
11/26/2019Royal Bank of CanadaReiterated RatingBuy$60.00Low
i
Rating by Beau Miller at Royal Bank of Canada
11/26/2019HC WainwrightReiterated RatingBuy$60.00Low
i
Rating by Andrew Fein at HC Wainwright
11/4/2019JPMorgan Chase & Co.Reiterated RatingBuy$50.00Low
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
11/1/2019HC WainwrightReiterated RatingBuy$60.00Medium
i
Rating by Andrew Fein at HC Wainwright
10/24/2019OppenheimerInitiated CoverageMarket Perform$44.00Medium
i
10/1/2019Royal Bank of CanadaInitiated CoverageOutperform$60.00Low
i
9/23/2019Cantor FitzgeraldBoost Price TargetOverweight$49.00 ➝ $56.00Low
i
9/13/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$21.00 ➝ $50.00Low
i
Rating by M. Goodman at SVB Leerink LLC
9/10/2019HC WainwrightSet Price TargetBuy$60.00Medium
i
Rating by Andrew Fein at HC Wainwright
9/10/2019JPMorgan Chase & Co.Reiterated RatingBuyHigh
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
9/10/2019Canaccord GenuityUpgradeHold ➝ Buy$29.00 ➝ $50.00High
i
9/9/2019Stifel NicolausSet Price TargetHold$39.00Medium
i
Rating by Paul Matteis at Stifel Nicolaus
9/9/2019Piper Jaffray CompaniesBoost Price TargetOverweight$35.00 ➝ $56.00High
i
9/9/2019CowenReiterated RatingBuy$66.00Low
i
9/9/2019Needham & Company LLCBoost Price TargetBuy$34.00 ➝ $60.00High
i
9/3/2019Stifel NicolausBoost Price TargetHold$24.00 ➝ $28.00High
i
8/27/2019Cantor FitzgeraldReiterated RatingOverweight$30.00 ➝ $40.00Low
i
8/5/2019Needham & Company LLCReiterated RatingBuy$34.00Low
i
8/1/2019HC WainwrightReiterated RatingBuyLow
i
Rating by A. Fein at HC Wainwright
7/31/2019JPMorgan Chase & Co.Set Price TargetBuy$32.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
7/31/2019Bank of AmericaSet Price TargetBuy$31.00N/A
i
Rating by Tazeen Ahmad at Bank of America Co.
7/23/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$40.00 ➝ $34.00High
i
7/1/2019Needham & Company LLCReiterated RatingBuy$40.00Low
i
5/31/2019Raymond JamesBoost Price TargetStrong-Buy$40.00 ➝ $43.00Low
i
5/3/2019HC WainwrightReiterated RatingBuyHigh
i
5/2/2019JPMorgan Chase & Co.Reiterated RatingBuy$31.00High
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
4/25/2019Cantor FitzgeraldReiterated RatingBuy$30.00Medium
i
Rating by Charles Duncan at Cantor Fitzgerald
3/3/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
2/28/2019Piper Jaffray CompaniesBoost Price TargetOverweight$30.00Low
i
2/27/2019Canaccord GenuityBoost Price TargetHold ➝ In-Line$23.00 ➝ $27.00High
i
Rating by Sumant Kulkarni at Canaccord Genuity
2/27/2019Cantor FitzgeraldReiterated RatingBuy$30.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
12/10/2018Canaccord GenuityInitiated CoverageHold ➝ Hold$23.00Medium
i
12/5/2018Cantor FitzgeraldReiterated RatingBuy$30.00Low
i
Rating by Charles Duncan at Cantor Fitzgerald
11/16/2018UBS GroupInitiated CoverageNeutral$39.00Low
i
11/12/2018SVB LeerinkInitiated CoverageMarket Perform$21.00High
i
Rating by M. Goodman at SVB Leerink LLC
11/7/2018Cantor FitzgeraldSet Price TargetBuy$30.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
11/3/2018JPMorgan Chase & Co.Reiterated RatingBuyMedium
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
11/1/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$27.00 ➝ $30.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
11/1/2018HC WainwrightReiterated RatingBuy$60.00High
i
Rating by Andrew Fein at HC Wainwright
10/31/2018Cantor FitzgeraldSet Price TargetBuy$27.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
10/15/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$25.00 ➝ $27.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
10/10/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$22.00 ➝ $25.00High
i
10/2/2018Cantor FitzgeraldSet Price TargetBuy$25.00Medium
i
Rating by Charles Duncan at Cantor Fitzgerald
9/21/2018Piper Jaffray CompaniesInitiated CoveragePositiveHigh
i
9/20/2018Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$25.00High
i
9/20/2018Cantor FitzgeraldSet Price TargetBuy$25.00High
i
Rating by C. Duncan at Cantor Fitzgerald
8/29/2018Cantor FitzgeraldReiterated RatingBuy$25.00Low
i
Rating by Charles Duncan at Cantor Fitzgerald
8/23/2018Cantor FitzgeraldInitiated CoverageOverweight$25.00High
i
Rating by C. Duncan at Cantor Fitzgerald
8/9/2018JMP SecuritiesLower Price TargetMarket Outperform ➝ Market Outperform$50.00 ➝ $27.00High
i
8/9/2018HC WainwrightReiterated RatingBuy$60.00High
i
Rating by A. Fein at HC Wainwright
8/7/2018Stifel NicolausInitiated CoverageHold ➝ Hold$17.00Low
i
8/6/2018Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$19.00High
i
7/1/2018JPMorgan Chase & Co.Set Price TargetBuy$50.00Low
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
5/16/2018HC WainwrightReiterated RatingBuyMedium
i
Rating by A. Fein at HC Wainwright
4/10/2018JPMorgan Chase & Co.Set Price TargetBuy$50.00High
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
11/8/2017HC WainwrightReiterated RatingBuy$60.00N/A
i
Rating by A. Fein at HC Wainwright
11/7/2017CowenReiterated RatingBuy$46.00N/A
i
10/12/2017Jefferies Financial GroupReiterated RatingBuy$47.00N/A
i
10/9/2017SVB LeerinkReiterated RatingMarket PerformN/A
i
10/6/2017The Goldman Sachs GroupReiterated RatingNeutral$45.00N/A
i
10/5/2017JPMorgan Chase & Co.Set Price TargetBuy$50.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
10/5/2017Piper Jaffray CompaniesReiterated RatingBuy$54.00 ➝ $61.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
10/5/2017Bank of AmericaBoost Price TargetBuy ➝ Positive$40.00 ➝ $46.00N/A
i
10/5/2017JMP SecuritiesBoost Price TargetOutperform$47.00 ➝ $50.00N/A
i
10/5/2017HC WainwrightReiterated RatingBuy$60.00N/A
i
Rating by A. Fein at HC Wainwright
10/2/2017LADENBURG THALM/SH SHReiterated RatingBuy$48.00 ➝ $50.00Low
i
9/17/2017Needham & Company LLCReiterated RatingBuy$49.00Low
i
8/10/2017CowenReiterated RatingOutperform$42.00 ➝ $46.00High
i
8/9/2017Piper Jaffray CompaniesSet Price TargetBuy$54.00High
i
Rating by Charles Duncan at Piper Jaffray Companies
8/9/2017HC WainwrightReiterated RatingBuy$60.00High
i
Rating by A. Fein at HC Wainwright
5/22/2017Rodman & RenshawReiterated RatingBuy$60.00Low
i
5/10/2017HC WainwrightReiterated RatingBuyLow
i
Rating by A. Fein at HC Wainwright
4/12/2017Jefferies Financial GroupReiterated RatingBuy$47.00Low
i
4/5/2017Needham & Company LLCReiterated RatingBuy$49.00Low
i
3/3/2017HC WainwrightReiterated RatingBuy$60.00N/A
i
3/1/2017Needham & Company LLCReiterated RatingBuy$49.00N/A
i
2/7/2017Piper Jaffray CompaniesReiterated RatingOverweight$44.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
2/2/2017LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$49.00 ➝ $48.00N/A
i
1/24/2017Needham & Company LLCReiterated RatingBuy$49.00N/A
i
1/24/2017CowenReiterated RatingOutperform$42.00N/A
i
1/14/2017CowenReiterated RatingOutperform$42.00N/A
i
1/11/2017JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
12/28/2016SVB LeerinkReiterated RatingMarket Perform$29.00N/A
i
Rating by P. Matteis at SVB Leerink LLC
12/23/2016HC WainwrightReiterated RatingBuy$60.00N/A
i
12/23/2016Piper Jaffray CompaniesReiterated RatingOverweight$44.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
12/23/2016Needham & Company LLCReiterated RatingBuy$49.00N/A
i
12/21/2016JPMorgan Chase & Co.Reiterated RatingOverweight$49.00N/A
i
11/11/2016The Goldman Sachs GroupInitiated CoverageNeutral$28.00N/A
i
11/10/2016CowenReiterated RatingOutperform$42.00N/A
i
11/8/2016SVB LeerinkReiterated RatingHold$29.00N/A
i
Rating by P. Matteis at SVB Leerink LLC
11/8/2016Bank of AmericaUpgradeNeutral ➝ Buy$35.00N/A
i
10/24/2016Needham & Company LLCReiterated RatingBuy$49.00N/A
i
10/19/2016Roth CapitalReiterated RatingNeutral$25.00N/A
i
Rating by M. Higgins at Roth Capital
10/17/2016CowenReiterated RatingOutperform$42.00N/A
i
10/12/2016Piper Jaffray CompaniesReiterated RatingOverweight$44.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
10/4/2016SVB LeerinkInitiated CoverageMarket Perform$34.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
9/30/2016CowenReiterated RatingOutperform$42.00N/A
i
Rating by Ritu Baral at Cowen Inc
9/25/2016HC WainwrightReiterated RatingBuy$60.00N/A
i
Rating by Andrew Fein at HC Wainwright
9/1/2016CowenReiterated RatingOutperform$42.00N/A
i
Rating by Ritu Baral at Cowen Inc
8/25/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
8/16/2016Piper Jaffray CompaniesReiterated RatingOverweight$44.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
8/10/2016JMP SecuritiesReiterated RatingBuy$45.00N/A
i
8/10/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
8/8/2016Piper Jaffray CompaniesReiterated RatingOverweight$44.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
8/8/2016HC WainwrightReiterated RatingBuy$60.00N/A
i
Rating by Andrew Fein at HC Wainwright
8/5/2016AegisDowngradeBuy ➝ Hold$54.00 ➝ $41.00N/A
i
Rating by R. Leboyer at Aegis
8/5/2016Needham & Company LLCReiterated RatingBuy$49.00N/A
i
Rating by Alan Carr at Needham & Company LLC
7/26/2016CowenReiterated RatingOutperform$42.00N/A
i
Rating by Ritu Baral at Cowen Inc
7/26/2016Needham & Company LLCReiterated RatingBuy$49.00N/A
i
Rating by Alan Carr at Needham & Company LLC
7/26/2016Piper Jaffray CompaniesReiterated RatingOverweight$44.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
7/8/2016Piper Jaffray CompaniesReiterated RatingOverweight$44.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
6/22/2016Bank of AmericaDowngradeBuy ➝ Neutral$40.00N/A
i
Rating by Tazeen Ahmad at Bank of America Co.
5/22/2016SVB LeerinkReiterated RatingHoldN/A
i
Rating by Paul Matteis at SVB Leerink LLC
5/19/2016Piper Jaffray CompaniesReiterated RatingPositive$44.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
5/6/2016HC WainwrightReiterated RatingBuyN/A
i
Rating by Andrew Fein at HC Wainwright
5/5/2016Piper Jaffray CompaniesReiterated RatingOverweight$44.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
5/5/2016CowenReiterated RatingOutperform$41.00N/A
i
Rating by Ritu Baral at Cowen Inc
5/3/2016SVB LeerinkDowngradeOutperform ➝ Market Perform$40.00 ➝ $35.00N/A
i
Rating by Paul Matteis at SVB Leerink LLC
(Data available from 4/22/2016 forward)
ACADIA Pharmaceuticals logo
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $20.87
$20.84
$21.74

50 Day Range

MA: $27.14
$20.39
$48.98

52 Week Range

Now: $20.87
$20.12
$58.72

Volume

1,944,462 shs

Average Volume

2,192,327 shs

Market Capitalization

$3.34 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.44

Frequently Asked Questions

What sell-side analysts currently cover shares of ACADIA Pharmaceuticals?

The following equities research analysts have issued stock ratings on ACADIA Pharmaceuticals in the last year: Bank of America Co., Canaccord Genuity, Cantor Fitzgerald, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Raymond James, Royal Bank of Canada, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, and Zacks Investment Research.
View the latest analyst ratings for ACAD.

What is the current price target for ACADIA Pharmaceuticals?

17 Wall Street analysts have set twelve-month price targets for ACADIA Pharmaceuticals in the last year. Their average twelve-month price target is $32.76, suggesting a possible upside of 52.6%. Cowen Inc has the highest price target set, predicting ACAD will reach $57.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $18.00 for ACADIA Pharmaceuticals in the next year.
View the latest price targets for ACAD.

What is the current consensus analyst rating for ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals currently has 12 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ACAD, but not buy more shares or sell existing shares.
View the latest ratings for ACAD.

What other companies compete with ACADIA Pharmaceuticals?

How do I contact ACADIA Pharmaceuticals' investor relations team?

ACADIA Pharmaceuticals' physical mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company's listed phone number is 858-558-2871 and its investor relations email address is [email protected] The official website for ACADIA Pharmaceuticals is www.acadia-pharm.com.